| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Radiopharmaceuticals | Oncology |
Recent Updates
Recently added Catalysts
Cerenome, Inc. Common Stock
$3.04
-0.15 (-4.7%)
Market Cap
20.86 M
EPS
-
P/E Ratio
-
Value Trade
-
-15.76 %
Week
-15.76 %
1 Month
-15.76 %
3 Month
-15.76 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
14.78 K
52 Week Range
-
% held by Insiders
0.99 %
% held by Institutions
17.37 %
Enterprise Value
12.27 M
Total Shares
171.62 M
Short %
10.42 %
Float Shares
167.16 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CNSY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CNSY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CNSY
Aug 20, 2026▼ -4.7%today
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
Cerenome presented key findings at the 2026 SNO/ASCO CNS Metastases Conference, highlighting the pharmacokinetics and safety of REYOBIQ in treating leptomeningeal metastases. The ongoing trials show promising safety signals and effective drug activity. Additionally, a cost-of-care analysis indicates that earlier detection and management could significantly reduce treatment costs for patients.
Read more →-CNSY
Aug 14, 2026▼ -13%on this news
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
Cerenome, Inc. reported its second quarter 2026 financial results, highlighting substantial progress in its CNS oncology platform and a successful rebranding from Plus Therapeutics. The company continues to enroll patients in multiple clinical trials for its lead therapeutic REYOBIQ, with no dose-limiting toxicities reported. However, the company experienced a significant increase in operating loss compared to the previous year.
Read more →-CNSY
Aug 13, 2026Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
Cerenome, through its subsidiary CNSide Diagnostics, has secured an in-network agreement with Health Care Service Corporation. This agreement marks a significant milestone, achieving the company's goal for commercial payer coverage by 2026. As a result, CNSide's coverage will now extend to over 150 million lives, enhancing access to its services.
Read more →-CNSY
Aug 6, 2026Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
Cerenome has chosen XiFin Empower RCM to manage revenue cycle and clearinghouse services for its CNSide platform. This strategic move aims to accommodate the anticipated billing volumes as the CNSide assay is scheduled to start billing in Q3 2026. The company is preparing for a backlog of tests and concurrent case billing.
Read more →-CNSY
Jul 31, 2026Cerenome Launches as an Integrated CNS Oncology Company
Cerenome, formerly Plus Therapeutics, has launched as an integrated company focusing on CNS oncology. The company aims to enhance the detection, treatment, and understanding of CNS cancers through precision diagnostics, targeted therapeutics, and artificial intelligence. This strategic rebranding signifies a commitment to innovation in the oncology field.
Read more →-CNSY
Jul 28, 2026Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
Plus Therapeutics, Inc. announced its participation in the 2026 SNO/ASCO CNS Metastases Conference, where it will present posters on its REYOBIQ™ clinical development program and CNSide® diagnostic platform. This event signifies the company's commitment to advancing research in central nervous system metastases. The presentations aim to enhance awareness of their innovative therapies.
Read more →-CNSY
Jul 21, 2026Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics has announced a regional coverage agreement with Medical Mutual for its CNSide® cerebrospinal fluid assay, effective July 1, 2026. This agreement aims to improve access to diagnostic services for patients with metastatic CNS cancer. The coverage is expected to enhance treatment options and patient outcomes.
Read more →-CNSY
Jul 16, 2026Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
Plus Therapeutics has partnered with Genomic Testing Cooperative to integrate next-generation sequencing into its CNSide® CSF assay platform. This collaboration is expected to yield hundreds of DNA and RNA biomarkers from a single cerebrospinal fluid specimen. The initiative aligns with the updated NCCN Guidelines® which now recognize CSF circulating tumor cells.
Read more →-CNSY
Jul 14, 2026Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Plus Therapeutics announced that the updated NCCN guidelines continue to endorse cerebrospinal fluid (CSF) analysis for diagnosing and managing leptomeningeal metastases. The guidelines recommend CSF cytology follow-ups every 4 to 8 weeks for patients undergoing intrathecal therapy, highlighting the importance of ongoing patient monitoring.
Read more →Competitive Position
How CNSY ranks across every disease it competes inCompetitive Position is a premium feature
See how CNSY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial